Appraisal of Prognostic Interaction between Sidedness and Mucinous Histology in Colon Cancer: A Population-Based Study Using Inverse Probability Propensity Score Weighting

被引:4
作者
Wang, Zi-Xian [1 ]
Yang, Lu-Ping [1 ,2 ]
Wu, Hao-Xiang [1 ,2 ]
Yang, Dong-Dong [1 ]
Ding, Pei-Rong [3 ]
Xie, Dan [4 ]
Chen, Gong [3 ]
Li, Yu-Hong [1 ]
Wang, Feng [1 ]
Xu, Rui-Hua [1 ]
机构
[1] Sun Yat Sen Univ, Dept Med Oncol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, 651 Dong Feng Rd East, Guangzhou 510060, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Fac Med Sci, Guangzhou 510080, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Dept Colorectal Surg, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China
[4] Sun Yat Sen Univ, Dept Pathol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China
来源
JOURNAL OF CANCER | 2019年 / 10卷 / 02期
关键词
colon cancer; tumor side; mucinous histology; survival; surveillance; epidemiology; end results; COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; PROXIMAL COLON; BRAF MUTATION; STAGE-II; SURVIVAL; ADENOCARCINOMA; PREDICTS; CHEMOTHERAPY; SUBTYPES;
D O I
10.7150/jca.28014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Colon cancer with different sidedness (right vs. left) and histology (mucinous vs. non-mucinous) may represent different disease entities. We investigated whether the prognostic values of sidedness and histology differed according to each other. Materials and Methods: We analyzed 81342 patients with stage II-IV colon cancer from the Surveillance, Epidemiology, and End Results database between 2004 and 2012. Patients were divided into four subgroups on the basis of sidedness and histology: non-mucinous right-sided, non-mucinous left-sided, mucinous right-sided, and mucinous left-sided subgroups. Among each tumor stage, median overall survival (mOS) was compared between these subgroups after inverse probability propensity score weighting to handle confounding factors. Results: In the stage IV subgroup, the prognosis for non-mucinous left-sided tumors (weighted mOS, 24.5 months) was significantly better than that for non-mucinous right-sided tumors (weighted mOS, 16.5 months; P<0.001) and that for mucinous left-sided tumors (weighted mOS, 16.5 months; P<0.001), whereas the survival was similar between left-sided and right-sided tumors with the mucinous subtype (weighted mOS, 16.5 months for both; P=0.570; test for interaction between sidedness and histology, P-interaction<0.001), and between mucinous and non-mucinous tumors in the right-sided colon (weighted mOS, 16.5 months for both; P=0.207). Similar findings were detected in the stage III subgroup (P-interaction<0.001). In the stage II subgroup, the survival was comparable among the four sidedness-histology subgroups (P=0.159 and P-interaction=0.466). Conclusions: In stage III/IV colon cancer, the prognostic value of sidedness differed according to histology, and vice versa. By contrast, neither should be considered in risk stratification for stage II colon cancer.
引用
收藏
页码:388 / 396
页数:9
相关论文
共 40 条
[1]  
[Anonymous], JNCI J NATL CANC I
[2]  
[Anonymous], NCCN Clinical Practice Guidelines in Oncology - Breast Cancer
[3]  
[Anonymous], 2014, J CLIN ONCOL, DOI DOI 10.1200/JCO.2014.32.15_SUPPL.3600
[4]  
[Anonymous], HISTOLOGICAL CLASSIF
[5]   The performance of different propensity score methods for estimating marginal hazard ratios [J].
Austin, Peter C. .
STATISTICS IN MEDICINE, 2013, 32 (16) :2837-2849
[6]   Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer [J].
Catalano, V. ;
Loupakis, F. ;
Graziano, F. ;
Bisonni, R. ;
Torresi, U. ;
Vincenzi, B. ;
Mari, D. ;
Giordani, P. ;
Alessandroni, P. ;
Salvatore, L. ;
Fornaro, L. ;
Santini, D. ;
Baldelli, A. M. ;
Rossi, D. ;
Giustini, L. ;
Silva, R. R. ;
Falcone, A. ;
D'Emidio, S. ;
Rocchi, M. ;
Fedeli, S. Luzi .
ANNALS OF ONCOLOGY, 2012, 23 (01) :135-U111
[7]   Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy [J].
Catalano, V. ;
Loupakis, F. ;
Graziano, F. ;
Torresi, U. ;
Bisonni, R. ;
Mari, D. ;
Fornaro, L. ;
Baldelli, A. M. ;
Giordani, P. ;
Rossi, D. ;
Alessandroni, P. ;
Giustini, L. ;
Silva, R. R. ;
Falcone, A. ;
D'Emidio, S. ;
Fedeli, S. L. .
BRITISH JOURNAL OF CANCER, 2009, 100 (06) :881-887
[8]   Mucinous adenocarcinoma showing different clinicopathological and molecular characteristics in relation to different colorectal cancer subgroups [J].
Chiang, J. M. ;
Yeh, C. Y. ;
Changchien, C. R. ;
Chen, J. S. ;
Tang, R. ;
Chen, J. R. .
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2010, 25 (08) :941-947
[9]   Propensity score-matching methods for nonexperimental causal studies [J].
Dehejia, RH ;
Wahba, S .
REVIEW OF ECONOMICS AND STATISTICS, 2002, 84 (01) :151-161
[10]   The consensus molecular subtypes of colorectal cancer [J].
Guinney, Justin ;
Dienstmann, Rodrigo ;
Wang, Xin ;
de Reynies, Aurelien ;
Schlicker, Andreas ;
Soneson, Charlotte ;
Marisa, Laetitia ;
Roepman, Paul ;
Nyamundanda, Gift ;
Angelino, Paolo ;
Bot, Brian M. ;
Morris, Jeffrey S. ;
Simon, Iris M. ;
Gerster, Sarah ;
Fessler, Evelyn ;
Melo, Felipe De Sousa E. ;
Missiaglia, Edoardo ;
Ramay, Hena ;
Barras, David ;
Homicsko, Krisztian ;
Maru, Dipen ;
Manyam, Ganiraju C. ;
Broom, Bradley ;
Boige, Valerie ;
Perez-Villamil, Beatriz ;
Laderas, Ted ;
Salazar, Ramon ;
Gray, Joe W. ;
Hanahan, Douglas ;
Tabernero, Josep ;
Bernards, Rene ;
Friend, Stephen H. ;
Laurent-Puig, Pierre ;
Medema, Jan Paul ;
Sadanandam, Anguraj ;
Wessels, Lodewyk ;
Delorenzi, Mauro ;
Kopetz, Scott ;
Vermeulen, Louis ;
Tejpar, Sabine .
NATURE MEDICINE, 2015, 21 (11) :1350-1356